公开(公告)号：US11135214B2

公开(公告)日：2021-10-05

申请号：US16410851

申请日：2019-05-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch

IPC: A01N37/00 ,  A61K31/215 ,  A01N37/12 ,  A01N37/44 ,  A61K31/24 ,  A01N25/00 ,  A61K31/472 ,  A61P25/08 ,  A61K9/00

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20230405023A1

公开(公告)日：2023-12-21

申请号：US18248663

申请日：2021-04-09

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch ,  Rostam Namdari

IPC: A61K31/635 ,  A61K31/4166

CPC classification number: A61K31/635 ,  A61K31/4166

Abstract: Provided are methods for treating diseases or conditions associated with Nav1.6 activity in a patient, comprising administering to said patient (S)-4((1-benzylpyrrolidin-3-yl)(methypamino)-2-fluoro-5-methyl-N(thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof, wherein the patient is also being administered a strong inducer of cytochrome P450 3A4 (CYP3A4).

公开(公告)号：US20250108044A1

公开(公告)日：2025-04-03

申请号：US18791918

申请日：2024-08-01

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Cynthia Louise Harden ,  Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/24

Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240316033A1

公开(公告)日：2024-09-26

申请号：US18679045

申请日：2024-05-30

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/08

CPC classification number: A61K31/472 ,  A61K9/0053 ,  A61P25/08

Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240342156A1

公开(公告)日：2024-10-17

申请号：US18415139

申请日：2024-01-17

Applicant: Xenon Pharmaceuticals Inc.

Inventor： James Philip Johnson, JR. ,  Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P23/00

CPC classification number: A61K31/472 ,  A61K9/0053 ,  A61P23/00

Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US11091441B2

公开(公告)日：2021-08-17

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US12178811B2

公开(公告)日：2024-12-31

申请号：US17093183

申请日：2020-11-09

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Cynthia Louise Harden ,  Gregory N. Beatch

IPC: A61K31/472 ,  A61K9/00 ,  A61P25/24

Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.

公开(公告)号：US20240279182A1

公开(公告)日：2024-08-22

申请号：US18540582

申请日：2023-12-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

CPC classification number: C07D217/04 ,  C07B2200/13

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.